Drugs / Lidocaine w/ epi
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06047366 Background | Dec 2023 → May 2024 | pulpitis | Indiana University | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lidocaine w/ epi | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06047366 ↗ |
| Route | Other | “1 cartridge of buffered 2% lidocaine w/ 1:100k epi via inferior alveolar nerve block (IANB)” NCT06047366 ↗ |